ArticlePediatric nephrology (Berlin, Germany)2013
Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome?
Article in Pediatric nephrology (Berlin, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children.Frontiers in pediatrics · 2021Pooled it
- Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Medicine · 2016Pooled it
- The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis.Scientific reports · 2015Pooled it
- Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- B cell depletion with rituximab in children with steroid-sensitive nephrotic syndrome: does depletion duration change outcome?Pediatric nephrology (Berlin, Germany) · 2026Article
- Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey.Pediatric nephrology (Berlin, Germany) · 2023Article
- B cell phenotype, activity, and function in idiopathic nephrotic syndrome.Pediatric research · 2023Review
- Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2022Observational
- Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study.Pediatric nephrology (Berlin, Germany) · 2022Article
- Prophylactic rituximab administration in children with complicated nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021Article
- Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2020Review
- Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.Pediatric rheumatology online journal · 2019Article
- Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values.World journal of clinical cases · 2019Article
- Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.Pediatric nephrology (Berlin, Germany) · 2019Observational
- Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.Frontiers in immunology · 2019Article
- Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.Pediatric nephrology (Berlin, Germany) · 2018Review
- Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.British journal of clinical pharmacology · 2018Article
- Nephrotic syndrome: Rituximab in childhood steroid-dependent nephrotic syndrome.Nature reviews. Nephrology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab (RTX) is a promising strategy for treating steroid-dependent idiopathic nephrotic syndrome (SDNS). RTX induces profound B-cell depletion, suggesting hypogammaglobulinemia as a potential side effect after long-term treatment. PATIENTS AND
methodsWe analyzed immunoglobulin G (IgG) levels in 12 pediatric patients on RTX with a B-cell depletion of a minimum of 3 months and compared the results to 16 patients on orally administered immunosuppressive drugs, such as mycophenolate mofetil (MMF) and/or cyclosporine A (CyA). All patients were in stable remission of SDNS at the time of IgG analysis.
resultsIgG levels in the RTX group before RTX introduction were 6.2 ± 1.0 g/L and were not significantly different from the MMF/CyA group (8.2 ± 2.5 g/L). In the MMF/CyA group, five patients had at least one episode of hypogammaglobulinemia. In two of them, this episode was prolonged (>3 months), and only one required IgG supplementation. In the RTX group, eight patients had decreased IgG levels before RTX infusion. After RTX, hypogammaglobulinemia persisted in seven among those eight patients. No decreased IgG plasma levels were noted in patients with normal baseline IgG levels before RTX treatment.
conclusionRTX does not seem to directly induce decreased IgG levels in patients with SDNS, but it seems to prolong a preexisting low IgG levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.